[BLCM] Bellicum Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 14.61 Change: 0.99 (7.27%)
Ext. hours: Change: 0 (0%)

chart BLCM

Refresh chart

Strongest Trends Summary For BLCM

BLCM is in the medium-term down -74% below S&P in 7 months. In the long-term down -88% below S&P in 2 years and down -97% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-2.81 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -93.99% Sales Growth - Q/Q-93.99% P/E-4.03
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-43.58% ROE-44.27% ROI
Current Ratio69.87 Quick Ratio Long Term Debt/Equity Debt Ratio0.01
Gross Margin Operating Margin-3029.56% Net Profit Margin-4346.19% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-10 K Cash From Investing Activities-930 K Cash From Operating Activities-7.03 M Gross Profit
Net Profit-7.76 M Operating Profit-7.81 M Total Assets188.27 M Total Current Assets185.01 M
Total Current Liabilities2.65 M Total Debt Total Liabilities2.91 M Total Revenue110 K
Technical Data
High 52 week7.23 Low 52 week1.08 Last close1.08 Last change-8.47%
RSI21.25 Average true range0.12 Beta1.54 Volume289.04 K
Simple moving average 20 days-26.41% Simple moving average 50 days-37.02% Simple moving average 200 days-64.52%
Performance Data
Performance Week-21.74% Performance Month-37.21% Performance Quart-65.05% Performance Half-66.97%
Performance Year-82.32% Performance Year-to-date-63.01% Volatility daily3.93% Volatility weekly8.79%
Volatility monthly18.01% Volatility yearly62.37% Relative Volume166.33% Average Volume644.42 K
New High New Low

News

2019-11-08 07:00:00 | Bellicum Pharmaceuticals Presents Encouraging Preclinical Data for GoCAR-NK Cell Program at Society for Immunotherapy of Cancer Annual Meeting

2019-11-07 02:53:36 | Edited Transcript of BLCM earnings conference call or presentation 6-Nov-19 10:00pm GMT

2019-11-06 19:15:12 | Bellicum Pharmaceuticals BLCM Reports Q3 Loss, Lags Revenue Estimates

2019-11-06 16:15:00 | Bellicum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Operational Update

2019-10-31 16:05:05 | Bellicum Pharmaceuticals Announces Presentation on CAR-NK Cell Program at SITC 2019

2019-10-30 07:30:05 | Bellicum Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Corporate Update

2019-10-29 10:33:02 | Earnings Preview: Bellicum Pharmaceuticals BLCM Q3 Earnings Expected to Decline

2019-10-26 08:57:17 | Introducing Bellicum Pharmaceuticals NASDAQ:BLCM, The Stock That Tanked 95%

2019-09-30 16:07:56 | Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-09-23 10:54:02 | Top Ranked Momentum Stocks to Buy for September 23rd

2019-09-03 14:53:12 | Do Insiders Own Lots Of Shares In Bellicum Pharmaceuticals, Inc. NASDAQ:BLCM?

2019-08-30 16:08:07 | Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-08-28 16:05:00 | Bellicum Pharmaceuticals to Participate in Three Healthcare Investor Conferences during September

2019-08-21 16:05:00 | Bellicum Pharmaceuticals Announces Aggregate Gross Proceeds of $69.6 Million from $139.6 Million Public Offering and Private Placement

2019-08-20 15:47:19 | Houston pharma co. raises $69.6M through public offering, private placement

2019-08-20 15:47:19 | Houston pharma co. raising $139.6M through public offering, private placement

2019-08-16 10:56:15 | CORRECTING and REPLACING -Bellicum Pharmaceuticals, Inc.

2019-08-16 08:30:00 | Bellicum Pharmaceuticals Announces Pricing of Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement

2019-08-15 17:37:00 | Bellicum Pharmaceuticals Announces Proposed $53.0 Million Public Offering of Preferred Stock and Warrants with Concurrent Private Placement

2019-08-05 18:15:10 | Bellicum Pharmaceuticals BLCM Reports Q2 Loss, Tops Revenue Estimates

2019-08-05 16:15:00 | Bellicum Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Operational Update

2019-07-30 10:38:02 | Bellicum Pharmaceuticals BLCM May Report Negative Earnings: Know the Trend Ahead of Q2 Release

2019-07-19 07:32:12 | Should You Worry About Bellicum Pharmaceuticals, Inc.'s NASDAQ:BLCM CEO Pay?

2019-07-08 08:00:00 | Bellicum Pharmaceuticals Announces Rivo-cel™ Achieves Primary Endpoint in Pediatric Registrational Trial

2019-06-13 11:53:21 | Does Bellicum Pharmaceuticals, Inc. NASDAQ:BLCM Have A High Beta?

2019-06-01 09:00:00 | Bellicum Pharmaceuticals Provides Interim Data for BPX-601 in Patients with Metastatic Pancreatic Cancer for Presentation at ASCO Annual Meeting

2019-05-31 19:00:00 | Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Bellicum Pharmaceuticals, Inc. NASDAQ: BLCM and Encourages Bellicum Investors to Contact the Firm

2019-05-31 16:14:03 | Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-05-29 16:05:00 | Bellicum Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference

2019-05-20 08:38:00 | BLCM Alert: Johnson Fistel, LLP Announces Investigation of Bellicum Pharmaceuticals, Inc.; Long Term Investors Encouraged to Contact Firm

2019-05-15 16:05:00 | Bellicum Pharmaceuticals to Present Updated Results for BPX-601 at the 2019 ASCO Annual Meeting

2019-05-07 10:30:02 | Bellicum Pharmaceuticals BLCM May Report Negative Earnings: Know the Trend Ahead of Q1 Release

2019-05-07 08:55:12 | Bellicum Pharmaceuticals BLCM Reports Q1 Loss, Tops Revenue Estimates

2019-05-07 07:30:00 | Bellicum Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Operational Update

2019-03-27 07:30:00 | Bellicum Pharmaceuticals to Participate in Jefferies 6th Annual IO Cell Therapy Summit

2019-03-13 15:22:52 | Edited Transcript of BLCM earnings conference call or presentation 12-Mar-19 9:00pm GMT

2019-03-12 16:01:00 | Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2018

2019-03-12 07:35:34 | Bellicum Pharmaceuticals Q4 Earnings Preview

2019-03-05 07:00:00 | Bellicum Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call and Webcast on Tuesday, March 12, 2019

2019-01-30 07:30:00 | Report: Developing Opportunities within Waste Connections, Performance Food Group, HealthEquity, PS Business Parks, Adverum Biotechnologies, and Bellicum Pharmaceuticals — Future Expectations, Projections Moving into 2019

2019-01-22 12:26:15 | How Bellicum Pharmaceuticals, Inc. NASDAQ:BLCM Could Add Value To Your Portfolio

2019-01-22 08:40:01 | Aratana Therapeutics PETX in Focus: Stock Moves 6.8% Higher

2018-12-27 09:47:02 | Bellicum Pharmaceuticals Enters Oversold Territory

2018-12-24 10:08:03 | Jazz JAZZ Falls as Sleep Drug Gets Extended Review From FDA

2018-12-20 07:00:00 | Bellicum Pharmaceuticals Announces Appointment of Judith Klimovsky, M.D., to Board of Directors

2018-12-14 07:00:00 | Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer at ESMO-IO

2018-12-13 07:00:00 | Bellicum Pharmaceuticals Appoints Atabak Mokari as Chief Financial Officer

2018-12-11 09:22:02 | Novan Announces Top-Line Data From Mid-Stage Molluscum Study

2018-12-02 10:30:00 | Bellicum Announces Data Presentation at ASH 2018 Demonstrating Low Rates of Cancer Recurrence in Pediatric AML and ALL Patients Treated with Rivo-cel

2018-12-01 14:00:00 | Bellicum Announces Interim Results Showing Rimiducid Controlled GvHD in Patients Treated with Rivo-cel Following a Stem Cell Transplant